Nonalcoholic Fatty Liver Disease

Angelo H. Paredes, Dawn M. Torres, Stephen A. Harrison*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

70 Scopus citations

Abstract

As the hepatic manifestation of the metabolic syndrome, nonalcoholic fatty liver disease (NAFLD) has become the most common cause of asymptomatic liver enzyme elevations in Western nations. Although it is easy to diagnose NAFLD, a liver biopsy is currently required to diagnose nonalcoholic steatohepatitis (NASH). Patients with NASH are those at greatest risk of progression to cirrhosis and, thus, treatment efforts are targeted to these individuals. Although currently there are no FDA-approved treatments for NASH, a multidisciplinary approach that addresses comorbid conditions and promotes modest weight loss comprises the backbone of therapy.

Original languageEnglish
Pages (from-to)397-419
Number of pages23
JournalClinics in Liver Disease
Volume16
Issue number2
DOIs
StatePublished - May 2012
Externally publishedYes

Keywords

  • Diagnosis
  • Nonalcoholic fatty liver disease (NAFLD)
  • Nonalcoholic steatohepatitis (NASH)
  • Treatment

Fingerprint

Dive into the research topics of 'Nonalcoholic Fatty Liver Disease'. Together they form a unique fingerprint.

Cite this